| scholarly article | Q13442814 |
| P50 | author | Fernando Schmitt | Q37382197 |
| Paul A VanderLaan | Q59085821 | ||
| Lester Layfield | Q87872132 | ||
| P2093 | author name string | Sinchita Roy-Chowdhuri | |
| Hormoz Ehya | |||
| Neal I Lindeman | |||
| Oscar Lin | |||
| Michael Roh | |||
| Zubair Baloch | |||
| Susan J Hsiao | |||
| Kim Geisinger | |||
| Nikoletta Sidiropoulos | |||
| P2860 | cites work | Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials | Q24625201 |
| Expression and rearrangement of the ROS1 gene in human glioblastoma cells | Q24630982 | ||
| Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma | Q24650843 | ||
| Analysis of Pre-Analytic Factors Affecting the Success of Clinical Next-Generation Sequencing of Solid Organ Malignancies | Q26783605 | ||
| The Utilization of Cytologic Fine-Needle Aspirates of Lung Cancer for Molecular Diagnostic Testing | Q26824315 | ||
| Guideline for the acquisition and preparation of conventional and endobronchial ultrasound-guided transbronchial needle aspiration specimens for the diagnosis and molecular testing of patients with known or suspected lung cancer | Q26864375 | ||
| ROS1 rearrangements define a unique molecular class of lung cancers | Q27851700 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Molecular markers: Implications for cytopathology and specimen collection | Q28087155 | ||
| Thyroid transcription factor-1: a review | Q28202870 | ||
| Napsin A, a member of the aspartic protease family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinomas | Q28640483 | ||
| Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer | Q29547564 | ||
| Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 | ||
| Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS | Q34023414 | ||
| p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma | Q34067972 | ||
| Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular | Q34159011 | ||
| Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic? | Q34571689 | ||
| EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non–small cell lung carcinoma patients | Q34777840 | ||
| Clinical next‐generation sequencing successfully applied to fine‐needle aspirations of pulmonary and pancreatic neoplasms | Q34871953 | ||
| PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation | Q34996125 | ||
| Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel | Q35043965 | ||
| Significance of c-MET overexpression in cytotoxic anticancer drug-resistant small-cell lung cancer cells | Q35051630 | ||
| Multiplatform comparison of molecular oncology tests performed on cytology specimens and formalin-fixed, paraffin-embedded tissue. | Q35237841 | ||
| Utility of five commonly used immunohistochemical markers TTF-1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases | Q35561933 | ||
| Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes | Q35584933 | ||
| Factors affecting the success of next-generation sequencing in cytology specimens. | Q35730088 | ||
| Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity | Q35870655 | ||
| Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification | Q35875227 | ||
| Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients | Q36043762 | ||
| Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers | Q36608839 | ||
| Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK-Rearranged Lung Adenocarcinomas | Q36612415 | ||
| The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer | Q37263479 | ||
| Preanalytic parameters in epidermal growth factor receptor mutation testing for non-small cell lung carcinoma: A review of cytologic series | Q37296060 | ||
| Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing | Q37832381 | ||
| EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities | Q37852662 | ||
| Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing | Q37866183 | ||
| c-MET as a potential therapeutic target and biomarker in cancer | Q37962905 | ||
| Targeting c-MET in the battle against advanced nonsmall-cell lung cancer | Q38079495 | ||
| Personalized therapy on the horizon for squamous cell carcinoma of the lung. | Q38089287 | ||
| p40 (ΔNp63) is more specific than p63 and cytokeratin 5 in identifying squamous cell carcinoma of bronchopulmonary origin: a review and comparative analysis. | Q38156118 | ||
| EGFR analysis: current evidence and future directions. | Q38195265 | ||
| Biomarkers in lung adenocarcinoma: a decade of progress | Q38254232 | ||
| Unexpected TTF-1 Positivity in a Subset of Gastric Adenocarcinomas | Q38384011 | ||
| The lung-restricted marker napsin A is highly expressed in clear cell carcinomas of the ovary | Q38389308 | ||
| Challenges and opportunities of next-generation sequencing: a cytopathologist's perspective | Q38591866 | ||
| The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma | Q39136930 | ||
| Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non | Q39323520 | ||
| Using "residual" FNA rinse and body fluid specimens for next-generation sequencing: An institutional experience | Q40195925 | ||
| The diagnostic utility of the triple markers Napsin A, TTF-1, and PAX8 in differentiating between primary and metastatic lung carcinomas. | Q40477156 | ||
| Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. | Q40609922 | ||
| Fine-needle aspiration of lymphadenopathy of suspected infectious etiology | Q40815774 | ||
| ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers. | Q41059959 | ||
| Molecular testing in lung cancer: fine-needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publication. | Q42225243 | ||
| Pyrosequencing Analysis of EGFR and KRAS Mutations in EUS and EBUS-Derived Cytologic Samples of Adenocarcinomas of the Lung | Q42287584 | ||
| Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer | Q43008635 | ||
| Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung | Q43561078 | ||
| Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors | Q44250446 | ||
| Sample features associated with success rates in population-based EGFR mutation testing | Q44285228 | ||
| EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. | Q46113744 | ||
| Ancillary techniques on direct-smear aspirate slides: a significant evolution for cytopathology techniques | Q46138162 | ||
| Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. | Q46762821 | ||
| Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections | Q47316045 | ||
| Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics | Q48337801 | ||
| Poor cell block adequacy rate for molecular testing improved with the addition of Diff-Quik-stained smears: Need for better cell block processing | Q50214316 | ||
| Thyroid transcription factor 1 and Napsin A double stain: utilizing different vendor antibodies for diagnosing lung adenocarcinoma | Q50499430 | ||
| Co-expression of TTF-1 and neuroendocrine markers in the human fetal lung and pulmonary neuroendocrine tumors. | Q50598751 | ||
| Utilization of p40 (ΔNp63) with p63 and cytokeratin 5/6 immunohistochemistry in non-small cell lung carcinoma fine-needle aspiration biopsy | Q50765727 | ||
| Optimal specimen processing of fine needle aspirates of non‐hodgkin lymphoma | Q51001675 | ||
| Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens | Q51563657 | ||
| TTF-1 expression in pulmonary adenocarcinomas | Q51716382 | ||
| Various Antibody Clones of Napsin A, Thyroid Transcription Factor 1, and p40 and Comparisons With Cytokeratin 5 and p63 in Histopathologic Diagnostics of Non-Small Cell Lung Carcinoma | Q52844020 | ||
| EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens | Q53238557 | ||
| Detection of EGFR gene mutations using the wash fluid of CT-guided biopsy needle in NSCLC patients | Q53419512 | ||
| Accuracy of classifying poorly differentiated non-small cell lung carcinoma biopsies with commonly used lung carcinoma markers | Q53582166 | ||
| The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma | Q54266360 | ||
| The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: a single South East Asian laboratory's analysis of 670 cases | Q54300490 | ||
| Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis | Q54446617 | ||
| Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. | Q54465286 | ||
| Zeroing in on ROS1 Rearrangements in Non–Small Cell Lung Cancer | Q54493078 | ||
| Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. | Q54644565 | ||
| ΔNp63 (p40) and Thyroid Transcription Factor-1 Immunoreactivity on Small Biopsies or Cellblocks for Typing Non-small Cell Lung Cancer: A Novel Two-Hit, Sparing-Material Approach | Q56779202 | ||
| Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study | Q57819980 | ||
| Preparation of Cell Blocks for Lung Cancer Diagnosis and Prediction: Protocol and Experience of a High-Volume Center | Q57940967 | ||
| Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine | Q63199223 | ||
| Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms | Q72132796 | ||
| Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas | Q83221091 | ||
| A Study of ΔNp63 Expression in Lung Non-Small Cell Carcinomas | Q83517159 | ||
| Subclassification of non-small cell lung cancer by cytologic sampling: a logical approach with selective use of immunocytochemistry | Q84669413 | ||
| Next-generation sequencing and the cytopathologist | Q86450176 | ||
| Young investigator challenge: Validation and optimization of immunohistochemistry protocols for use on cellient cell block specimens | Q87303881 | ||
| p40 is the best marker for diagnosing pulmonary squamous cell carcinoma: comparison with p63, cytokeratin 5/6, desmocollin-3, and sox2 | Q87828321 | ||
| P433 | issue | 12 | |
| P921 | main subject | cytopathology | Q1881849 |
| P304 | page(s) | 1000-1009 | |
| P577 | publication date | 2016-08-26 | |
| P1433 | published in | Diagnostic Cytopathology | Q15750060 |
| P1476 | title | Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology | |
| P478 | volume | 44 |
| Q91198259 | A practical guide for ancillary studies in pulmonary cytologic specimens |
| Q93366803 | Cell block cellularity: A comparison of two fixatives and their impact on cellularity |
| Q91339462 | Committee II: Guidelines for cytologic sampling techniques of lung and mediastinal lymph nodes |
| Q61809917 | Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: Techniques and Challenges |
| Q94486073 | Evolution of guidelines for respiratory cytology by the Papanicolaou Society of Cytopathology |
| Q52587597 | Feasibility of endobronchial ultrasound transbronchial needle aspiration for massively parallel next-generation sequencing in thoracic cancer patients |
| Q39356534 | Lung cancer samples preserved in liquid medium: One step beyond cytology |
| Q89898362 | Metabonomics by proton nuclear magnetic resonance in human pleural effusions: A route to discriminate between benign and malignant pleural effusions and to target small molecules as potential cancer biomarkers |
| Q47653216 | PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. |
| Q57713176 | The new guidelines of Papanicolaou Society of Cytopathology for respiratory specimens: Assessment of risk of malignancy and diagnostic yield in different cytological modalities |
| Q97648949 | Use of cytology centrifuged supernatants improves cost and turnaround time for targeted next generation sequencing |
Search more.